
|Articles|October 8, 2014
- NSCLC (Issue 4)
- Volume 4
- Issue 1
The Benefit of Treating Lung Cancer with Immunotherapy
Author(s)Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, from Yale-New Haven in Connecticut, discusses the benefit of treating lung cancer with immunotherapy.
Advertisement
Articles in this issue
about 11 years ago
The Implementation of Personalized Medicine for Lung Cancer Patientsabout 11 years ago
The Cancer Genome Atlas Plays Role in Future Therapies for NSCLCabout 11 years ago
In Practice: Systemic Treatment for Metastatic NSCLCabout 11 years ago
The Importance of Biomarkers for Lung Cancerabout 11 years ago
Clinical Trial Profile: The OAK Studyabout 11 years ago
Optimizing of Therapeutic Sequencing Being Studied in NSCLCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
2
Trial Data Show Efficacy, Tolerability of Nivolumab Plus Visogromab in MIBC
3
FDA Grants Orphan Drug Status to Novel CD33-Directed Immunotherapy for AML
4
Domvanalimab Combo Shows Enriched First-Line Efficacy in Advanced GI Cancers
5








































